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Introduction
The presentation of antigenic molecules is fundamental to 
host defence and immune regulation. The MHC class I and II 
molecules present peptide antigens to T cells and the molecular 
mechanisms of peptide loading and editing are relatively well 
understood1–3. However, the mechanism by which lipid antigens 
are loaded onto the CD1 family of antigen-presenting molecules 
remains poorly understood. CD1 molecules have structural 
similarity to MHC class I, including association with β-2- 
microglobulin (β2m), but unlike MHC molecules, CD1 mol-
ecules are non-polymorphic and the antigen-binding grooves of 
CD1 molecules are extremely hydrophobic, allowing the binding 
of most classes of lipids including phospholipids, glyceroli-
pids, lysolipids and glycolipids possessing a huge variety of 
glycosylated head groups4.
Of the five CD1 family members, antigen presentation by CD1d 
is best characterised. CD1d undergoes complex cellular traf-
ficking in a manner similar to that of MHC class II. Following 
synthesis in the endoplasmic reticulum, CD1d traffics via the 
Golgi apparatus to the plasma membrane, and is then internal-
ised and trafficked through early and late endocytic compart-
ments before being returned to the plasma membrane5, where 
CD1d-lipid complexes are recognized by the T cell receptor 
(TCR) of natural killer T (NKT) cells. Invariant NKT (iNKT) 
cells, which bear an invariant TCR and are characteristically 
potently activated by recognition of CD1d loaded with the 
synthetic glycolipid α-galactosylceramide (α-GalCer), are innate-
like T cells involved in the orchestration of immune responses6.
Lipid antigens are embedded in cellular membranes7 and 
thus are not directly accessible to the lumenal, lipid-binding 
groove of CD1 molecules. The loading of lipid antigen onto 
CD1 molecules therefore requires the action of lipid transfer 
proteins (LTPs) for efficient antigen presentation. The loading 
of lipids onto CD1d can occur in the ER, at the cell surface and 
in endocytic compartments. Relatively little is known about 
how lipid specificity is determined, and studies using secreted 
or recycling, surface-cleavable human CD1d found differences 
in the lipid repertoire bound to CD1d, reflecting the lipids 
present in the compartments through which it had trafficked8–10. 
Different LTPs are present in the different cellular locations 
where lipid antigen loading occurs and are likely to determine 
the lipid repertoire bound to CD1 molecules11. Interestingly, 
the late endocytic/lysosomal compartment is the site of both 
glycolipid catabolism and lipid loading of CD1d and the resident 
LTPs function in both these processes. Importantly, the anti-
genicity of glycolipids can be regulated by processing of their 
glycan headgoups prior to presentation to T cells, highlighting 
the complex interplay between these two pathways12,13.
The LTPs present in the lysosomal compartments include 
ganglioside monosialic 2 activator (GM2A), Niemann-Pick 
type C 2 (NPC2) and four saposin (Sap) proteins. SapA, SapB, 
SapC and SapD are the products of the proteolytic cleav-
age of a prosaposin (PSAP) precursor and are each small, 
non-enzymatic proteins possessing three disulphide bonds that 
stabilise an extremely heat-resistant helical structure. The 
saposins can exist in a “closed” monomeric, globular confor-
mation or, at low pH, adopt a more “open” conformation, form-
ing higher-order oligomers enclosing a hydrophobic cavity into 
which lipid acyl chains can be buried14–19. Each saposin functions 
in conjunction with specific hydrolases to facilitate the degra-
dation of different glycosphingolipids and the loss of saposin 
function phenotypically resembles the loss of the associated 
hydrolases20–25. There are two proposed mechanisms for how 
saposins assist in lipid presentation to hydrolases: the “solu-
biliser” model, whereby saposins encapsulate lipids within a 
hydrophobic oligomeric complex for presentation to soluble 
enzymes, and the “liftase” model, where saposins bind directly 
to membranes destabilising them, allowing membrane-associated 
hydrolases access to lipid substrates. Structural and cell-based 
evidence exists to support both these models19,26–29. These 
two models are also relevant for the proposed mechanisms 
by which saposins load lipids onto CD1 molecules30. SapB is 
thought to behave as a “solubiliser”, forming protein-lipid 
complexes that enhance lipid loading of CD1 molecules, while 
SapC associates with membranes and may facilitate lipid 
loading at the membrane surface.
The evidence for saposin-mediated lipid loading of CD1 mol-
ecules comes from animal knockout studies, cell-based assays 
and in vitro assays. Knockout of PSAP in mice results in the 
dramatic loss of presentation of endogenous iNKT cell ligands 
by CD1d31. The presentation of exogenous lipid antigens, such 
as α-GalCer, is impaired in PSAP knockout or knockdown 
cells31–34. In vitro assays have identified that all the saposins, as 
well as the other lysosomal LTPs, GM2A and NPC2, are capa-
ble of transferring lipids onto CD1 molecules31,35. However, 
some LTPs appear to be more efficient than others at loading 
specific lipid antigens onto different CD1 molecules30,33,36. 
Specificity within the saposin family in this process has been 
explored via in vitro assays identifying SapB as the dominant 
saposin for the loading of lipid antigens onto CD1d. Specifi-
cally, incubation of CD1d with SapB and α-GalCer has been 
shown to enhance the stimulation of iNKT cells33,34 and SapB 
            Amendments from Version 1
We thank the reviewers for their insightful comments. We have 
revised the manuscript following their helpful suggestions as 
follows:
We acknowledge that the lack of a detectable interaction does 
not necessarily mean that there is no interaction. We have 
edited the abstract and discussed why an interaction too weak 
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direct protein-protein interactions are crucial for several different 
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can mediate lipid binding to CD1d in T cell independent assays33 
suggesting a direct role for this specific saposin in lipid load-
ing of CD1d. The ability of SapB to facilitate and enhance lipid 
exchange on CD1d has also been monitored in vitro via iNKT 
TCR binding to CD1d following incubation with lipids alone 
or lipids plus SapB34. These in vitro assays implicate SapB as a 
“lipid editor” that facilitates the loading and unloading of lipid 
antigens onto CD1d.
Due to the hydrophobic property of lipids, their exposure to 
aqueous solutions is thermodynamically unfavourable. There-
fore, lipid transfer between hydrophobic lipid-binding cavities 
of proteins requires direct interaction of the protein components 
to provide continuous shielding of the lipid from the aqueous 
phase37. This hypothesis is supported by the fact that other 
known lipid transfer proteins directly interact with the protein 
receiving the lipid38–40. However, several publications report 
a failure to detect a direct interaction between saposins and 
human CD1d11,33,34. Unfortunately, these reports do not show 
any data or detail the approaches used to monitor binding and 
the implication is that these interactions exist but are weak and 
very transitory. Therefore we have used a number of robust 
and sensitive biochemical and structural techniques to moni-
tor direct interactions between SapB and CD1d. Using multiple 
approaches in a range of conditions we do not observe any 
evidence of a direct interaction between CD1d and SapB.
Methods
Cloning and cell line production
Codon-optimised cDNA was synthesized (GeneArt) encoding 
human β2m (residues 21-119, Uniprot P61769) and the extra-
cellular domain of human CD1d (residues 20-301, Uniprot 
P15813) with a C-terminal hexahistiding tag (CD1d-H6). A modi-
fied version of the piggyBac target protein plasmid PB-T-PAF41 
was constructed retaining the N-terminal secretion signal but 
with the Protein A fusion removed. CD1d-H6 and β2m were 
individually cloned into this modified vector, using SpeI and 
AscI restriction-endonuclease sites, to produce PB-T-CD1d-H6 
and untagged PB-T-β2m. For production of an inducible, stable 
co-expression cell line, HEK293F cells were quadruple- 
transfected with PB-T-CD1d-H6, PB-T-β2m, PB-RN and PBase 
using a DNA mass ratio of 5:5:1:1 and transfected cells were 
selected with geneticin using the established protocol for the 
piggyBac expression system41.
Codon-optimised cDNA was synthesized (GeneArt) encod-
ing the segment of human PSAP corresponding to SapB 
(residues 195-274, Uniprot P07602) and subcloned into the bac-
terial expression vector pET-15b using NcoI and XhoI restriction 
endonuclease sites to produce untagged protein. SapB was also 
subcloned into the mammalian expression vector pHLsec42 using 
the restriction enzymes AgeI and KpnI to encode a C-terminally 
H6-tagged protein.
Protein expression and purification
Protein expression of CD1d-β2m complex in the HEK293F 
co-expression cell line was induced with 2 µg/mL doxycycline 
and expression media was collected over a 2 month period. 
CD1d-H6 was purified from conditioned media by nickel affinity 
chromatography in phosphate-buffered saline (PBS) pH 7.4 
and eluted using PBS containing 300 mM imidazole. CD1d-β2m 
was further purified by size exclusion chromatography on 
a Superdex 200 column (GE Healthcare) equilibrated in 
cross-linking buffer (20 mM HEPES pH 7.0, 150 mM NaCl) for 
interaction assays or distinct buffers (described below) for crys-
tallisation experiments. CD1d-β2m was concentrated to 2 mg/mL 
and stored at 4 °C for up to one month.
To produce deglycosylated CD1d-β2m, cells were treated with 
5 µM kifunensine at the same time as protein expression was 
induced. CD1d-β2m was purified by nickel affinity purifica-
tion and eluted with 100 mM citrate pH 4. CD1d-β2m protein 
was buffer exchanged into 100 mM citrate pH 5.5, using 
repeated rounds of dilution and concentration using a centrifugal 
concentrator, concentrated to 2 mg/mL and incubated with 
3125 units of Endoglycosidase H (Endo H; New England Biolabs) 
per milligram of protein for 3 hours at room temperature. 
Deglycosylated CD1d-β2m was purified by size exclusion 
chromatography (as described above).
Untagged SapB was expressed in Escherichia coli Origami 
(DE3) cells and purified as described previously43. Briefly, 
cleared lysate was heat-treated, precipitated proteins were 
cleared by centrifugation and supernatant containing SapB was 
dialysed overnight in the presence of 20 µg/mL DNAse 
against anion exchange buffer (50 mM Tris pH 7.4, 25 mM NaCl). 
SapB was further purified by anion exchange chromatography 
(HiTrap QSepharose column) followed by size-exclusion chro-
matography (HiLoad 16/600 Superdex 75 column) in 50 mM 
Tris pH 7.4, 150 mM NaCl. Purified SapB was concentrated 
to 16 mg/mL and stored at 4 °C.
His6-tagged SapB was expressed in HEK293F cells by poly-
ethylenimine-based transient transfection. After 4 days, 
SapB-H6 was purified from conditioned media by nickel affinity 
and size exclusion chromatography with a Superdex 75 column 
(GE Healthcare) in cross-linking buffer. Prior to crystallisation 
trials (but not cross-linking assays), the tag was removed by 
incubation with 1.2 U/mL Carboxypeptidase A-agarose at 
25°C overnight followed by incubation with Ni-NTA resin to 
remove tagged protein. The supernatant containing untagged 
SapB was separated from Carboxypeptidase A-agarose and 
Ni-NTA agarose by passing through a gravity flow column.
α-GalCer loading
Endogenously purified lipids were exchanged for the lipid 
α-GalCer (Avanti Lipids) based on a protocol used to obtain 
crystal structures of α-GalCer-loaded CD1d44,45. Lipid was 
resuspended in DMSO at 1 mg/mL and dissolved by heating 
the solution at 80°C for 10 min, with brief sonication and 
vortexing every 3 minutes. CD1d-β2m and SapB were incu-
bated with a 3-fold molar excess of α-GalCer in PBS overnight 
at room temperature. α-GalCer-loaded proteins were then sepa-
rated from free α-GalCer by size exclusion chromatography 
with a Superdex 200 10/300 column equilibrated in 20 mM 
HEPES pH 7.0, 150 mM NaCl. α-GalCer-loaded proteins were 
used within 24 hours after size exclusion chromatography 
to avoid significant hydrolysis of the lipid.
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Equilibrium binding assay
Ni-NTA agarose beads were loaded with a saturating amount 
of CD1d-β2m, and complete capture of CD1d-β2m was veri-
fied by measuring the absorbance of the supernatant at 280 nm. 
Saturated beads were washed three times in equilibrium assay 
buffer (50 mM HEPES pH 7.0, 150 mM NaCl, 0.05% digitonin, 
2.5 mM CaCl2, 2.5 mM MgCl2). Serial dilutions (1:1) of 
CD1d-β2m-saturated beads were made in equilibrium assay 
buffer supplemented with unloaded Ni-NTA beads to equalize 
the bead volume across all samples. SapB was added at a final 
concentration of 680 nM in equilibrium assay buffer. The reac-
tion was incubated with shaking at room temperature for 1 hour. 
The supernatant containing unbound SapB was separated from 
the beads by centrifugation (800g, 2 min) followed by sepa-
ration with a Micro-Spin column (Pierce) (800g, 2 min) to 
remove all beads. The supernatant was analysed by SDS-PAGE 
followed by staining with SYPRO Ruby. For analysis of bead 
samples, these were boiled in SDS-PAGE loading dye, separated 
by SDS-PAGE and detected by Coomassie staining.
Cross-linking assay
Amine-reactive cross-linking agents disuccinimidyl sulfox-
ide (DSSO) and PEGylated bis(sulfosuccinimidyl)suberate 
(BS(PEG)5) were dissolved in DMSO and added to 10 µM 
CD1d-β2m alone, 20 µM SapB alone or 10 µM CD1d + 20 µM 
SapB with final cross-linker concentrations of 0, 200 µM or 1 mM 
in cross-linking buffer. The reaction was incubated for 30 min 
at room temperature and terminated by incubation with 20 mM 
Tris pH 8 for 15 min. The reaction products were analysed by 
SDS-PAGE followed by Coomassie staining.
Crystallography
Crystallization experiments were performed in 96-well nanolitre- 
scale sitting drops (200 nL protein plus 200 nL of precipitant) 
equilibrated at 20°C against 80 µL reservoirs of precipitant. 
The crystals reported here were grown in drops containing the 
following components:
Crystal form (i) (Figure 4B) contained glycosylated CD1d-H6-β2m 
(13.5 mg/mL) + 2-fold molar excess of unglycosylated SapB 
(4.7 mg/mL) in 150 mM NaCl, 50 mM Tris pH 7.4 and 
grew against a reservoir containing 20% w/v polyethylene 
glycol (PEG) 6000, 0.1 M HEPES pH 7 and 0.2 M calcium 
chloride.
Crystal form (ii) (Figure 4B) contained glycosylated 
CD1d-H6-β2m (12.4 mg/mL) + 2-fold molar excess of 
glycosylated SapB (after tag removal) (4.3 mg/mL) in 20 mM 
HEPES pH 7.0, 150 mM NaCl and grew against a reservoir 
containing 20 mM 1,6-hexanediol, 20 mM 1-butanol, 20 mM 
1,2-propanediol, 20 mM 2-propanol, 20 mM 1,4-butanediol, 
20 mM 1,3-propanediol, 0.1 M bicine/Trizma base pH 8.5, 
12.5% w/v PEG 1000, 12.5% w/v PEG 3350 and 12.5% v/v 
2-methyl-2,4-pentanediol.
Crystal form (iii) (Figure 4B) contained α-GalCer-loaded 
glycosylated CD1d-H6-β2m (11.9 mg/mL) + 2-fold molar excess 
of α-GalCer-loaded unglycosylated SapB (4.2 mg/mL) in 50 mM 
Tris pH 7.4, 150 mM NaCl and grew against a reservoir 
containing 0.1 M sodium acetate pH 5.0, 20% w/v PEG 6000 
and 0.2 M ammonium chloride.
Crystal form (iv) (Figure 4B) contained deglycosylated CD1d-
H6-β2m (13.3 mg/mL) + 2-fold molar excess of unglycosylated 
SapB (4.7 mg/mL) in 20 mM citrate pH 6, 150 mM NaCl, and 
grew against a reservoir containing 16% v/v PEG 500 mono-
methylether, 8% w/v PEG 20000, 0.1 M bicine/Trizma base 
pH 8.5, 30 mM sodium nitrate, 30 mM sodium phosphate 
dibasic and 30 mM ammonium sulfate.
Crystal form (v) (Figure 4D) contained deglycosylated 
CD1d-H6-β2m (6.5 mg/mL) + 2-fold molar excess of unglyco-
sylated SapB (2.3 mg/mL) in 100 mM citrate pH 6.0, 150 mM 
NaCl and grew against a reservoir containing 20% w/v 
PEG 3350, 0.1 M bis-Tris propane pH 7.5 and 0.2 M di-sodium 
malonate.
X-ray data collection and molecular replacement
Crystals were cryoprotected in reservoir solution supple-
mented with 20% v/v glycerol and flash-cooled by plunging 
into liquid nitrogen. Diffraction data were recorded at Dia-
mond Light Source (DLS) on beamlines I03, I04 and I04-1. 
Diffraction data were indexed and integrated using the automated 
data processing pipelines at DLS46 implementing XIA2 DIALS47, 
XIA2 3dii or autoPROC and STARANISO48 depending on the 
extent of anisotropic diffraction, then scaled and merged using 
AIMLESS49. Version numbers for crystallography data process-
ing software are detailed in Table 1. The model for molecu-
lar replacement was generated using the published structure of 
CD1d-β2m bound to lysophosphatidylcholine50 (PDB ID 3U0P, 
chains A and B), using phenix.sculptor (Phenix v1.14-3260)51,52 
to remove the lipid ligand from the model and revert the 
glycosylation site mutations present in this structure. Molecu-





autoPROC (v1.0.5) and STARANISO 
(v1.10.15)
XIA2 (v0.5.771) 3dii (version January 
26, 2018)
XIA2 (v0.5.764) DIALS 
(v1.12.2)
Scaling software AIMLESS (v0.7.2) AIMLESS (v0.7.3) AIMLESS (v0.7.3)
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followed by rigid body refinement using phenix.refine54. Molecu-
lar replacement into the highly anisotropic data (Crystal form 
(iii)) was carried out using both the isotropic and anisotropi-
cally processed data, resulting in the same solution. Maps were 
inspected using COOT (v0.8.9)55. Structure figures were rendered 
using PyMOL (v2.1.0, Schrödinger LLC).
SDS-PAGE analysis of crystals
For each crystallisation condition tested, several crystals were 
harvested from the crystallisation drop and washed by trans-
ferring to a drop of reservoir solution to remove uncrystal-
lised protein components. Crystals were then transferred to a 
second drop of reservoir solution and dissolved in SDS-PAGE 
loading buffer. Alternatively, large crystals from which data had 
been collected at the synchrotron were recovered into SDS-
PAGE loading buffer from the crystal-mounting loop. Individual 
crystal components were analysed by SDS-PAGE followed by 
Coomassie staining.
Results
Purification of CD1d-β2m complex from a human cell line
Several strategies have been developed previously for the 
purification of CD1d including refolding from E. coli inclusion 
bodies56, baculovirus-insect cell expression50 and mammalian 
expression systems57. An important consideration for CD1d pro-
tein expression and purification is the inclusion of the essential 
partner protein β2m. In a manner similar to the heavy chain of 
MHC class I, CD1d non-covalently associates with β2m and this 
association is required for maturation of its four glycan chains58. 
In order to obtain high quality, near-native CD1d protein for 
in vitro studies, we chose to co-express human CD1d with 
β2m in the mammalian suspension cell line HEK293F as 
this would confer correct folding, native post-translational 
modification and full glycosylation of CD1d. Initial trials 
using polyethylenimine-based transient co-transfection of 
CD1d and β2m resulted in very low yields. Thus we used a 
piggyBac-expression system41 to establish stable and inducible 
co-expression of full-length, untagged β2m with the ectodo-
main of CD1d possessing a C-terminal hexahistidine tag (H6) 
(Figure 1A). Both proteins were expressed with an N-terminal 
secretion signal sequence targeting synthesis to the endoplas-
mic reticulum, resulting in protein secretion into the media. This 
expression strategy results in CD1d molecules that are bound to 
endogenous human lipids acquired during folding in the endo-
plasmic reticulum and trafficking through the Golgi apparatus. 
CD1d-H6 was purified from conditioned media by nickel affin-
ity chromatography followed by size exclusion chromatography 
(Figure 1B and C). Untagged β2m co-purified with CD1d, 
indicating that both proteins are correctly folded and form 
a stable complex. Although some CD1d alone was puri-
fied, we were able to separate this from CD1d-β2m following 
size exclusion (Figure 1C). Using this expression system, 
we obtained a high yield (1 mg/100 mL media) of very pure 
CD1d-β2m protein. The yield was over 10 times higher than 
that obtained with transient co-transfection in the same 
cell line.
Purification of SapB
The four saposin proteins (SapA-D) are produced from the 
proteolytic cleavage of the precursor protein PSAP which 
normally occurs upon delivery to the lysosome. To produce 
recombinant SapB alone, the segment of human PSAP corre-
sponding to SapB (Figure 1D) was expressed in E. coli. Untagged 
SapB was purified following a well-established protocol43 
that exploits the heat stability of saposins followed by anion 
exchange and size exclusion chromatography (Figure 1E and F). 
Previous structural studies with E. coli-expressed SapB 
identified that it exists as a tight dimer that co-purifies with 
E. coli phosphatidylethanolamine14.
CD1d binding to SapB is not detectable using in vitro 
interaction assays
Classical pull-down experiments involve the capture and immo-
bilisation onto resin of a tagged bait protein followed by incuba-
tion with prey protein. Subsequent wash steps remove unbound 
protein leaving behind protein complexes for detection. How-
ever, as the concentration of free prey protein is reduced 
at each wash, the equilibrium is pushed towards complex 
dissociation, meaning this method is not well suited for the cap-
ture of weak or transient interactions. Using this approach, no 
interaction was detectable between immobilised CD1d-β2m 
and SapB. Therefore, an alternative approach was adopted 
to overcome the limitations of prey-depletion by using an 
in vitro equilibrium binding assay (Figure 2A). In this assay, the 
bait is bound to beads at a range of concentrations and the prey 
is added at a low, limiting concentration. Following incubation, 
and no wash steps, the supernatant is separated from the beads and 
unbound prey is detected using the sensitive protein dye SYPRO 
Ruby. Monitoring the depletion of prey from the supernatant by 
the large excess of bait protein, rather than monitoring complex 
formation directly, represents a more sensitive measure of binding 
and thus is optimised for weak or transient interactions59.
Equilibrium binding assays were carried out using CD1d-β2m 
as bait at a concentration range of 0-40 µM and with SapB as 
the prey at 680 nM. Previous in vitro studies have identified 
that SapB can load α-GalCer onto CD1d at a pH range between 
5 and 833. Although this exchange appears to be most effi-
cient at pH 6, this pH causes partial dissociation of the CD1d 
His-tag from the Ni-NTA resin. Therefore, the equilibrium 
binding assay was performed at pH 7. Previous work, and our 
preliminary experiments, showed that β2m dissociates from 
CD1d in the presence of detergent60. However, the gentle deter-
gent digitonin was found to cause minimal disruption of the 
CD1d-β2m complex60 and was used in this assay. Despite the 
use of this optimised approach, no binding of SapB to CD1d 
could be detected (Figure 2B). In these conditions, at high 
CD1d-β2m concentrations, a small amount of β2m is detectable 
in the supernatant due to dissociation from CD1d (Figure 2B). 
By comparing how little appears to be lost based on the 
Coomassie-stained bead samples this highlights the sensitivity 
of this technique and of the SYPRO Ruby stain for protein 
detection.
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Figure  1.  Purification of CD1d-β2m  and SapB. A. A His-tagged construct encoding the extracellular domain of CD1d (CD1d-H6) was 
co-expressed with untagged full-length β2m in mammalian cells. B. Size exclusion chromatography (SEC) showing co-purification of 
CD1d-H6 with β2m. C. SDS-PAGE of SEC fractions. The indicated fractions containing β2m-associated CD1d were used in subsequent 
experiments. D. Untagged SapB (residues 195-274 of the precursor protein PSAP) was expressed in E. coli. E. SEC of SapB after 
multi-step purification. F. SDS-PAGE of SEC fractions. The indicated fractions were used in subsequent experiments.
Figure 2. Equilibrium binding assay of CD1d-β2m and SapB. A. Schematic diagram illustrating the equilibrium binding assay protocol. 
B. Increasing concentrations of CD1d-β2m were bound to beads and detected by Coomassie-stained SDS-PAGE. After incubation with 
SapB, unbound SapB was detected in supernatants by SYPRO Ruby-stained SDS-PAGE. The lipids bound to CD1d-β2m and SapB in this 
experiment are the endogenous lipids they co-purify with following expression in human cells and E. coli, respectively. C. As for panel B but 
with CD1d-β2m and SapB both pre-loaded with the lipid α-GalCer. D. As for panel B but with only SapB pre-loaded with the lipid α-GalCer.
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Previous studies have shown that the ectodomain of CD1d 
co-purifies with a broad range of cellular lipids following 
synthesis and trafficking through the secretory pathway, but is 
likely to be primarily loaded with sphingomyelin8–10. SapB co- 
purifies with E. coli phosphatidylethanolamine14, a lipid 
species that has also been shown to bind CD1d61. Although it 
seems likely that this lipid composition for SapB and CD1d 
should be compatible with protein-protein interactions required 
for lipid exchange, lipid loading onto CD1d has only been for-
mally demonstrated in vitro for a few lipids, and in particular 
α-GalCer33,34. Therefore, both proteins were pre-loaded with 
α-GalCer prior to performing the equilibrium binding assay. 
However, this variation also did not result in a detectable inter-
action between SapB and CD1d (Figure 2C). To exclude 
the possibility that a strong interaction between CD1d and SapB 
only occurs when SapB exchanges a lower affinity antigen 
for α-GalCer, we repeated the equilibrium binding assay where 
SapB was pre-loaded with α-GalCer while CD1d retained 
the co-purified endogenous lipids (Figure 2D). Again, there was 
no substantial depletion of SapB from the supernatant in this 
assay. These results strongly suggest that CD1d and SapB 
do not directly interact in vitro, or that their interaction is 
extremely weak with a Kd > 40 µM.
In vitro cross-linking does not capture an interaction 
between CD1d and SapB
Cross-linking of proteins using short chemical tethers that react 
with surface-exposed lysine side-chains can be used to capture 
transient or weak interactions. Both CD1d and SapB have 
several surface-exposed lysines, and of particular importance, 
lysine residues are present near the lipid-binding groove of 
CD1d where we would predict SapB to bind (Figure 3A and B). 
Therefore, it is possible that CD1d and SapB interact in a way 
that is amenable to intermolecular cross-linking of surface 
lysines by amine-reactive cross-linkers. We used cross-linkers 
of different lengths to maximise the chances of capturing an inter-
action: DSSO, with a 10.3 Å spacer arm, and BS(PEG)5, with a 
21.7 Å spacer arm. CD1d-β2m and SapB were incubated with 
these cross-linkers either alone or following mixing (Figure 3C). 
For the CD1d-β2m samples alone, cross-linking between CD1d 
and β2m is clearly evident, as expected. There is also some 
evidence of additional higher order oligomers, probably due to 
the large number of surface lysines on both CD1d and β2m. How-
ever, no additional cross-linking products were observed when 
CD1d-β2m and SapB were incubated together with the cross-
linkers. This indicates that CD1d-β2m and SapB do not interact 
together in a conformation that is amenable to cross-linking.
Figure 3. In vitro cross-linking of CD1d-β2m and SapB. A. Ribbon diagram of the structure of CD1d (beige) and β2m (pink)(PDB ID 3U0P) 
with the lipid antigen groove labelled (arrow). Surface-accessible lysine residues available for cross-linking are highlighted (red sticks). 
B. Ribbon diagram of the structure of a SapB dimer (yellow and orange, PDB ID 1N69) with bound lipid (in gray). Lysine residues are 
highlighted as in panel A. The N-linked glycosylation site of SapB is highlighted (blue sticks). C. Coomassie-stained SDS-PAGE of 
CD1d-β2m and unglycosylated SapB samples following incubation with cross-linkers of different lengths: DSSO (10.3 Å) or BS(PEG)5 
(21.7 Å). D. As for panel C but using CD1d-β2m and glycosylated SapB (gSapB).
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SapB possesses one N-linked glycosylation site on residue Asn21 
(Figure 3B), which remains unglycosylated when expressed 
in E. coli. Although unglycosylated SapB loads lipids onto 
CD1d33,34, it is possible that this glycan on SapB may increase 
its affinity for CD1d. Therefore, we repeated the cross-linking 
experiment following expression of His-tagged SapB 
in mammalian HEK293F cells, enabling the purifica-
tion of glycosylated protein. Following purification, two 
SapB-H6 species were present, with molecular weights of 
approximately 10 and 13 kDa, likely corresponding to ungly-
cosylated and glycosylated SapB-H6 (Figure 3D). It was not 
possible to separate these two SapB species, likely due to SapB 
dimerization, and so cross-linking experiments were carried out 
using this mixed sample (Figure 3D). However, we again did 
not observe formation of any additional cross-linked products 
when CD1d-β2m was incubated with glycosylated SapB-H6. 
We note that although the same amount of unglycosylated SapB 
(Figure 3C) and glycosylated SapB (Figure 3D) were used in 
cross-linking assays, the Coomassie-stained bands corresponding 
to glycosylated SapB appear much stronger. This increased 
staining may be due to the additional histidine residues in 
the affinity tag increasing the amount of Coomassie reagent 
binding to this small protein.
CD1d-β2m and SapB do not co-crystallise
An alternative method to capture weak, transient protein-protein 
interactions is to attempt co-crystallisation. In this experiment 
both protein components are mixed together at a range of 
concentrations and different molar ratios, then subjected to 
crystallisation trials. The benefit of using the sitting-drop vapour 
diffusion approach is that during the experiment the drop 
containing protein and precipitant gradually equilibrates with 
the reservoir, generally resulting in reduced drop volume and the 
progressive increase in concentration of the drop components. 
In this way, the protein components are steadily concen-
trated together with the aim of capturing an interaction that is 
otherwise extremely hard to measure using biochemical and 
biophysical assays62.
Extensive crystallisation trials containing both CD1d-β2m and 
SapB were performed, varying the following parameters: (1) 
protein concentration (6-13 mg/mL CD1d-β2m, 2-6 mg/mL 
SapB), (2) molar ratio of SapB to CD1d, taking into account the 
predicted dimeric state of SapB (2:1-3:1 SapB to CD1d); (3) full 
glycosylation or deglycosylation of protein components; and 
(4) lipid exchange for α-GalCer. Figure 4A shows an example 
of the high purity of the protein components that went into crys-
tallisation trials. These experiments yielded several different 
crystals in a range of conditions, a subset of which are 
shown in Figure 4B. To determine the composition of these 
crystals, two approaches were used depending on the quality of the 
crystals grown. The first approach, which can be used for any 
protein crystal, involves harvesting and washing the crystals 
in reservoir solution to remove residual uncrystallised 
components, then separating the proteins by SDS-PAGE followed 
by detection using Coomassie staining (Figure 4C, each gel lane 
corresponds to the above crystal in panel 4B). This revealed 
that both SapB and CD1d-β2m were capable of forming 
crystals but in none of the crystals grown did both compo-
nents crystallise together. The second approach used was to 
collect diffraction data for any crystals that diffracted to 5 Å 
resolution or better, then use molecular replacement to 
confirm the contents of the asymmetric unit (Table 2). Three 
crystal forms satisfied this criteria, including two that had also 
Figure 4. Crystallisation trials of CD1d-β2m and SapB. A. Coomassie-stained SDS-PAGE example of the purified protein sample used 
in crystallisation trials. B. Examples of four crystals (i)–(iv) grown in a range of conditions using different protein compositions. Scale bar 
represents 100 μm. C. Coomassie-stained SDS-PAGE of harvested and washed crystals shown in panel B. D. Image of the crystal that 
diffracted to highest resolution as described in Table 2. Scale bar represents 100 μm. Abbreviations: gCD1d-glycosylated CD1d, dgCD1d-
deglycosylated CD1d, gSapB-glycosylated SapB, and ugSapB-unglycosylated SapB.
Page 9 of 23
Wellcome Open Research 2019, 4:117 Last updated: 26 OCT 2019
Table 2. Data collection statistics and molecular replacement solutions. For Crystal 4B (iii) statistics 
have been included for data from a single crystal before (isotropic) and after anisotropic truncation and 
scaling using STARANISO. Values in parentheses are for the highest-resolution shell.
Data collection Crystal Fig 4B (iii) Crystal Fig. 4B (iv) Crystal Fig. 4D (v)
Beamline I04 I04-1 I03
Wavelength (Å) 0.9999 0.9159 0.9793
Processing package autoPROC + STARANISO XIA2 3dii XIA2 DIALS
Space group C 2 P 21 C 2
Cell dimensions
a,b,c (Å) 273.3, 88.0, 127.9 123.8, 122.9, 159.9 186.2, 57.1, 129.2
α,β,γ (°) 90, 114, 90 90, 95, 90 90, 100, 90
Isotropic Anisotropic
Resolution (Å) 124.71 – 4.97 
(5.05 – 4.97)
124.71 – 4.55 
(5.00 – 4.55)
123.27 – 3.49 
(3.55 – 3.49)
54.53 – 2.52 
(2.56 – 2.52)
Rmerge 0.438 (2.187) 0.198 (0.507) 0.161 (1.572) 0.072 (2.438)
Rpim 0.279 (1.366) 0.127 (0.323) 0.067 (0.663) 0.031 (1.028)
CC1/2 0.967 (0.322) 0.987 (0.704) 0.992 (0.714) 0.999 (0.813)
I/σI 1.9 (0.5) 3.4 (1.8) 6.9 (1.0) 10.9 (0.8)
Completeness (%) 99.8 (99.8) e* 80.0 (56.7) 
s* 39.2 (8.1)
99.8 (99.9) 99.8 (98.0)
Redundancy 3.4 (3.5) 3.4 (3.4) 6.9 (6.6) 6.7 (6.6)
Molecular replacement
# CD1-β2m/ASU 4 6 2
*ellipsoidal (e) and spherical (s) completeness are quoted for anisotropic data processing using STARANISO.
been tested using SDS-PAGE (Figure 4B (iii) and (iv) and 4D 
(v)). These three samples all contained CD1d-β2m only as 
confirmed by molecular replacement trials using multiple 
copies of all potential components as well as manual inspection 
of maps. In all datasets additional density was observed for 
unmodelled glycans on CD1d (deglycosylation of CD1d using 
Endo H leaves a residual acetylated glycosamine), confirming the 
validity of the molecular replacement solution. For several CD1d 
molecules, additional unmodelled density near the lipid-binding 
groove was evident that likely corresponds to partially-ordered 
lipid components. Further inspection of electron density maps 
revealed no evidence for the presence of SapB. For most 
molecules of CD1d in all three different crystal forms the pre-
dicted binding site for SapB (over the lipid-binding groove) was 
occupied by another copy of CD1d. The use of both SDS- 
PAGE analysis of all grown crystals and molecular replace-
ment solution of higher quality crystals confirmed that, despite 
extensive efforts with a broad range of CD1d-β2m/SapB 
combinations, these do not form a stable, crystallisable complex.
Discussion
Using highly purified components we have been unable to iden-
tify a direct interaction between CD1d-β2m and SapB in vitro. 
Several biochemical and structural approaches were imple-
mented that have the capacity to capture weak and transient 
interactions, including binding equilibrium assays, protein cross-
linking, and co-crystallisation trials. Various factors that may 
influence the strength or specificity of these interactions were 
tested, including different pH and buffer systems, exchange of 
the lipids loaded onto both protein components, and 
changing the glycosylation state of each protein. None of these 
variants resulted in the detection of a direct interaction. Our 
previous work studying saposin interactions with lysosomal 
hydrolases showed that although these interactions are sensitive 
to pH and salt concentrations, they were always detectable, and 
while detergent/lipid was required, neither the nature of the 
lipid/detergent nor the glycosylation state mattered19.
Direct protein-protein interactions are crucial for several differ-
ent lipid transfer pathways. The lipopolysaccharide (LPS) trans-
fer cascade resulting in Toll-like receptor 4 (TLR4) activation 
involves several lipid transfer steps. LPS binding protein (LBP) 
extracts LPS and transfers it onto the receptor CD14. CD14 then 
transfers LPS to the TLR4 co-receptor MD-2. A direct, high 
affinity (Kd  = 5.52 nM) interaction between LBP and CD14 is 
necessary for lipid transfer, and lipid transfer promotes rapid 
dissociation of CD14:LPS from LBP. Similarly, a direct 
interaction between CD14 and the TLR4:MD-2 complex is 
required for lipid transfer38. The transfer of lipids between 
proteins is also seen in the formation of Apolipoprotein B 
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(apoB)-containing lipoproteins. Microsomal Triglyceride Transfer 
protein assists this process by binding to apoB with high affin-
ity (Kd 10-30 nM)63 and transferring lipids onto apoB through an 
unknown mechanism. Both functions are required for lipopro-
tein assembly39. As another example, Niemann–Pick C1 (NPC1) 
and Niemann–Pick C2 (NPC2) proteins collaborate to export 
cholesterol from the lysosome. Soluble NPC2 binds choles-
terol in the lysosomal lumen, interacts with the middle lume-
nal domain of the multipass transmembrane protein NPC1 
and transfers cholesterol to NPC1 via a transfer tunnel linking 
the cholesterol-binding pockets of both proteins. The interac-
tion between NPC2 and NPC1 (Kd 0.4-2 µM) is required for 
cholesterol export40. In all cases, a high-to-medium affinity direct 
interaction between proteins engaged in lipid transfer is detect-
able. In this study, we were unable to detect a direct interaction 
between CD1d and SapB despite the assays being capa-
ble of detecting very weak interactions. Specifically, the 
equilibrium assay used in this study can detect protein inter-
actions where the dissociation constant is as weak as 40 µM. In 
the absence of avidity effects, interactions weaker than 40 µM 
are unlikely to be physiologically relevant. Furthermore, the 
cross-linking assay can detect short-lived, transient interactions 
and the co-crystallography technique uses very high concen-
trations of protein components allowing for the detection of 
very weak interactions. It therefore seems unlikely that an 
interaction that is undetectable by these methods could 
permit direct lipid exchange between SapB and CD1d.
The study of lipid loading of CD1 molecules is technically 
challenging as biochemical methods often require the inclu-
sion of detergents, which may interfere with lipid solubilisa-
tion and binding. Also, the detection of changes to CD1d-lipid 
complexes is limited by available reagents including specific 
antibodies and iNKT TCRs. However, the inability to identify 
a direct interaction between CD1d and SapB raises a number of 
important questions regarding the role of saposins in lipid antigen 
presentation.
It is well established that knockout of the saposin precursor 
protein PSAP results in impaired presentation of lipid antigens 
by CD1d. Due to the dual role of saposins in lipid loading and 
lipid processing, the absence of PSAP will not only alter CD1d 
lipid loading, but will also significantly alter the composition 
of the lysosomal lipidome. Indeed, the loss of a single saposin 
results in the cellular accumulation of multiple, different GSLs. 
For example, loss of SapB alone, in mice or in humans, results 
in the accumulation of sulfatides, globotriaosylceramide, and 
lactosylceramide64,65. Therefore, in saposin knockout and rescue 
models, the effects on antigen processing and the changes to 
local lipid concentrations may have indirect and unpredict-
able effects on CD1d loading in the lysosome. Similarly, 
cell-based assays that involve recognition of CD1d-lipid com-
plexes by NKT cells are complicated by the requirement of 
some glycolipid headgroups to be processed by lysosomal 
hydrolases12, a process that is itself dependent upon 
saposins.
In vitro assays testing the role of different saposins in 
facilitating lysosomal hydrolase activity identify some of the 
difficulties in determining specificity of saposin-lipid binding. 
For example, in vitro assays have identified that SapC and SapA 
are both able to enhance the activity of β-galactosylceramidase 
(GALC) to promote degradation of the galactosphingolipids66,67. 
However, this does not reflect the specificity of saposins in 
whole organisms as loss of SapA causes Krabbe disease, 
similar to that of loss of GALC, while mutations in SapC 
do not20,21,23–25. Why these in vitro assays do not recapitulate the 
specificity of saposins in a whole organism remains unclear 
but may suggest a non-specific detergent-like effect of saposins 
when present at relatively high concentrations. It is unclear 
whether a similar effect may be partially confounding the inter-
pretation of SapB influence on CD1d lipid loading. While 
in vitro studies demonstrating the ability of SapB to enhance 
CD1d stimulation of iNKT cells or binding to iNKT TCRs are 
very compelling regarding the importance of SapB in this proc-
ess, these do represent an indirect way of monitoring how SapB 
may be involved in lipid exchange33,34. In light of our data show-
ing no detectable interaction between CD1d and SapB, the 
question remains: how can SapB facilitate lipid editing 
without directly binding CD1d? Modelling of how SapB might 
facilitate lipid exchange identified a role for SapB in enhanc-
ing the kinetics of lipid exchange in a manner similar to that 
of Tapasin in peptide exchange on MHC class I molecules34. 
This comparison is driven by the crucial roles that Tapasin and 
SapB play in the binding and exchange of peptides or lipids, 
respectively, to the antigen-binding grooves of MHC class I 
or CD1d molecules. In order for Tapasin to carry out this role, 
it binds directly to MHC class I but as part of a larger complex 
including additional proteins2,68. Although the in vitro assays 
demonstrating the importance of SapB for CD1d lipid presenta-
tion did not require other proteins, it is possible that there may 
be additional factors involved in enhancing the affinity of SapB 
for CD1d in cells.
Additional factors may influence the efficiency of lipid load-
ing onto CD1d in cells. For example, the relative abundance 
of different LTPs in the lysosome may influence the lysosomal 
lipid composition, altering exchange kinetics. Therefore, it 
may be important that SapA-D exist in equimolar concentra-
tions in the endolysosome, as ensured by their production from a 
common precursor. If this is the case, studies involving indi-
vidual saposins or partial PSAP rescues will be difficult to 
interpret, potentially explaining some experimental inconsist-
encies. The lysosomal lipidome is not only influenced by the 
activity of saposins and sphingolipid processing hydrolases 
but also by the careful balance of other membrane components 
such as cholesterol and bis(monoacylglycero)phosphate that are 
crucial for endosomal vesicle formation. Lipid loading of CD1 
in endolysosomal compartments is highly complex, requiring the 
delicate interplay of lipid binding, lipid processing and lipid 
exchange. For now, the mechanism of transfer of lipids onto CD1 
molecules, as well as the molecular determinants of LTP binding 
specificity, remains unclear.
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Data availability
Underlying data
Figshare: Original data used in Figure 1, https://doi.org/10.6084/
m9.figshare.892670969.
Figshare: Original equilibrium binding assay gels used in 
Figure 2, https://doi.org/10.6084/m9.figshare.886438470.
Figshare: Original cross-linking gels used in Figure 3, https://doi.
org/10.6084/m9.figshare.893285671.
Figshare: Original gels and images used in Figure 4, https://doi.
org/10.6084/m9.figshare.893289872.
Apollo: Research data supporting “The lipid transfer pro-
tein Saposin B does not directly bind CD1d for lipid antigen 
loading”. https://doi.org/10.17863/CAM.4168373.
This project contains the following underlying data:
-    Original X-ray diffraction datasets, processed diffrac-
tion data, molecular replacement solutions for crystals 
(iii), (iv) and (v)
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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It is not clear if the authors have tried the equilibrium binding assay of unloaded CD1d-b2m with
aGalCer loaded Saposin B as additional control in Figure 2. This could be an important
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My major point about this work is that I could not tell which, if any, experiments also included
relevant lipid, particularly pre-loaded into saposin. Either key sentences in the MS should be
rewritten to avoid that impression (if it is wrong), or the MS should clearly include the caveat that
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On that basis, it has not been addressed if prolonged interaction only occurs when one of the
proteins is occupied by lipid. This might even be asymmetric so that prolonged interaction requires











The rationale for this work is explained in 2 sentences of the final paragraph of the Introduction.
This rationale is not explained as clearly as it might be. In the 1st sentence, do the authors mean
that the 3 refs were written to indicate that the lipid binding proteins must be able to bind each other












The different models should be described more, and the limits to the data mentioned in the 2nd





In addition, the Introduction and Discussion should both describe (in brief and extensive terms,
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Also in discussion of tapasin, describe if the relationship parallels the one envisaged here. Finally,











The estimated maximum level of Kd that these techniques would find is 40 μM (Fig 2B). The





















State whether conditions in Fig 2C were shown to permit transfer of lipid. Ideally, this should be
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While the authors' studies are particularly thorough and extensive, the reviewer still has reservation
to make a statement that this work could establish "comprehensively" that the role of saposin B in
lipid loading does not involve direct interaction with CD1d. As the authors mentioned that the "in
vivo" condition may be understandably different from the in vitro experimental conditions the
authors have extensively tried. For example, as the authors pointed out, in lysosomes, there are
multiple saposins present at possibly higher local concentrations, the potential "loading complex"
may requires additional proteineous factors, etc. Therefore, while all results strongly suggested





The additional factor is the pH in experimental condition may still affect the potential interaction
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The amount of cross-linked saposin/CD1d may be lower than detection limit in Commassie blue







In equilibrium binding assay with a-GalCer, the lipid exchange/editing can be imagined as
unloading of "endogenous" lipids in CD1d (co-purified from bacteria or mammalian cells) and
replacing with a-GalCer. It is unknown if both saposin and CD1d loaded with the same a-GalCer
lipid, whether this editing and saposin/CD1d interaction would occur. As antigen editing would be
stronger affinity antigen replacing the lower affinity antigen. It is strongly suggested that the same
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